Christian Hölscher

Overview

Best Publications

• Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology

  Rebecca Radde;Tristan Bolmont;Stephan A Kaeser;Janaky Coomaraswamy

  1149
  Citations

• An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

  Theresa R. Bomfim;Leticia Forny-Germano;Luciana B. Sathler;Jordano Brito-Moreira

  948
  Citations

• The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

  Paula L. McClean;Vadivel Parthsarathy;Emilie Faivre;Christian Hölscher

  745
  Citations

• Stimulation on the Positive Phase of Hippocampal Theta Rhythm Induces Long-Term Potentiation That Can Be Depotentiated by Stimulation on the Negative Phase in Area CA1 In Vivo

  Christian Hölscher;Roger Anwyl;Michael J. Rowan

  578
  Citations

• Nitric oxide, the enigmatic neuronal messenger: its role in synaptic plasticity

  Christian Hölscher

  578
  Citations

• Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.

  Kerry Hunter;Christian Hölscher

  569
  Citations

• Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence.

  Jessica Freiherr;Manfred Hallschmid;William H. Frey;Yvonne F. Brünner

  561
  Citations

• Common pathological processes in Alzheimer disease and type 2 diabetes: a review.

  Lin Li;Christian Hölscher

  493
  Citations

• Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology

  Adrian Olmos-Alonso;Sjoerd T. T. Schetters;Sarmi Sri;Katharine Askew

  490
  Citations

• TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

  Mychael V. Lourenco;Julia R. Clarke;Rudimar L. Frozza;Theresa R. Bomfim

  442
  Citations

• Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease.

  Paula L. McClean;Christian Hölscher

  382
  Citations

• Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

  Christian Hölscher

  327
  Citations

• Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system.

  Alison Hamilton;Christian Hölscher

  315
  Citations

• Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease.

  Talib Abbas;Emilie Faivre;Christian Hölscher

  307
  Citations

• Stress impairs performance in spatial water maze learning tasks.

  Christian Hölscher

  299
  Citations

• Glucocorticoid receptor and protein/RNA synthesis-dependent mechanisms underlie the control of synaptic plasticity by stress

  Lin Xu;Christian Holscher;Roger Anwyl;Michael J. Rowan

  296
  Citations

• Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

  W. Liu;Jaishree Jalewa;Mohit Sharma;G. Li

  237
  Citations

• Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.

  Christian Hölscher

  234
  Citations

• Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

  Alison Hamilton;Steven Patterson;David porter;Victor A Gault

  230
  Citations

• Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.

  Paula L. McClean;Victor A. Gault;Patrick Harriott;Christian Hölscher

  228
  Citations